What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners. The agreement, which also includes a team of biotech executives,
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Inc. (NASDAQ:BLUE – Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors purchased 1,893 put options on the stock. This is an increase of 28% compared to ...
EST Bluebird Bio (BLUE) trading halted, volatility trading pauseDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback